Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GLTX-001
- Development stage
- Preclinical
- Lead developer
- Goliver Therapeutics
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
GLTX-001 is an investigational cell therapy developed by GoLiver Therapeutics, consisting of an injectable solution of frozen allogeneic liver cells intended for rapid bedside preparation and administration. It is designed to protect the liver from acute and massive hepatocyte destruction and to accelerate the organ’s natural regenerative capacity, providing a readily available, off‑the‑shelf biomedicine for patients with severe liver injury or liver failure.[9][5]
- Other names
- allogeneic hepatocyteshuman pluripotent stem cell-derived hepatocyteshPSC-derived hepatocytes
Beyond the preview
Go deeper on GLTX-001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GLTX-001.